This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Progestogen only pill and cardiovascular disease (CVD) risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • based on the current evidence, the progestogen-only pill is probably a suitable alternative to the combined oral contraceptive pill in women still wishing to use an oral preparation when the combined oral contraceptive pill is contraindicated because of cardiovascular risk factors - however these women still need to be carefully screened and monitored
  • the limited available evidence does not support an association between cardiovascular disease and use of a POP (2)

Note though that in women with congenital long QT syndrome (LQTS)(3)

  • study evidence has shown that that progestin-only OC (oral contraceptive) was associated with a pronounced 2.8-fold increased risk of CEs (cardiac events) in women who did not receive beta-blocker therapy, while beta-blockers were highly protective during progestin-only OC treatment

Reference:

  1. FSRH (March 2015). Progestogen-only pills.
  2. Drug and Therapeutics Bulletin (2000);38 (1): 1-4.
  3. Abu-Zeitone A. et al. Oral contraceptive use and the risk of cardiac events in patients with long QT syndrome.Heart Rhythm. 2021; 11: 1170-1175

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.